Analytical performance of the FDA-cleared Parsortix(®) PC1 system

INTRODUCTION: The Parsortix(®) PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tumor cells from whole blood based on cell size and deformability. This r...

Descripción completa

Detalles Bibliográficos
Autores principales: Templeman, Amy, Miller, M. Craig, Cooke, Martin J., O’Shannessy, Daniel J., Gurung, Yuwaraj, Pereira, Tiago, Peters, Samuel G., Piano, Mario De, Teo, Manilyn, Khazan, Negar, Kim, Kyukwang, Cohen, Evan, Lopez, Heather B, Alvarez, Franklin, Ciccioli, Mariacristina, Pailhes-Jimenez, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434983/
https://www.ncbi.nlm.nih.gov/pubmed/37601320
http://dx.doi.org/10.33393/jcb.2023.2629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434983/
https://www.ncbi.nlm.nih.gov/pubmed/37601320
http://dx.doi.org/10.33393/jcb.2023.2629

Ejemplares similares